DNA
$6.83
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
Recent News
How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk
Analysts have been trimming their price targets on Ginkgo Bioworks Holdings, with bullish views moving to about US$12 from US$14 and more cautious calls dropping to around US$5 from US$9. These shifts line up with a more mixed narrative, where some analysts still see long term potential, while others are more focused on execution risk and the impact of recent business changes. As you read on, you will see how to track these evolving views and what they might mean for your own research on the...
A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration
Why Ginkgo Bioworks is back on investors’ radar Ginkgo Bioworks Holdings (DNA) has drawn fresh attention after reporting full year 2025 results that paired lower sales with a smaller net loss, alongside a new collaboration with Invaio Sciences on peptide based crop protection. See our latest analysis for Ginkgo Bioworks Holdings. The earnings release and Invaio collaboration have landed against a tough backdrop, with Ginkgo Bioworks Holdings’ 1 day share price return of 30.48% decline at...
Ginkgo Bioworks Q4 Earnings Call Highlights
Ginkgo Bioworks (NYSE:DNA) used its fourth-quarter earnings call to outline a sharpened strategic focus for 2026 centered on “autonomous labs,” while also detailing year-over-year declines in cell engineering revenue and continued progress on expense reductions and cash burn. 2026 focus shifts towa
Ginkgo Bioworks Holdings Inc (DNA) Q4 2025 Earnings Call Highlights: Strategic Shifts and ...
Ginkgo Bioworks Holdings Inc (DNA) focuses on autonomous labs and cash burn reduction while navigating revenue declines and restructuring impacts.
Ginkgo Bioworks Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q4 2025 earnings call